No scam. Hard to tell about a cure (genetic markers or a predetermined time needed). Remissions and improvements are assured for many, if not most. FDA is an unknown quantity, but likely working with Mayo to get the "low-order-liver" hold modified or removed, in the near future. This looks a sound investment, if your ticker is healthy.
I don't see how Tefferi (Mayo) can avoid talking about the liver observations related to Imetelstat dosage, and the FDA, liver related hold. That is what everyone is waiting to hear about. Are Mayo and the FDA "on the same page"? We should know tomorrow.
The FDA must be thinking about Imetelstat. If they believe that this is a dangerous drug they should tell the world. Their silence is deafening and serves nobodies' interests that puts the health and hope of these cancer patients first. The FDA is unwittingly destroying Geron investors (not their problem?). Some on these board are encouraging that thought, very successfully, with this concept: Geron is a one drug company, and that drug has failed, due to Geron or Mayo frauds, about live threatening liver side-effects (not true, IMO). Nothing is impossible, and some believe that man is not contributing to climate change.
We are assuming that both Scarlett & Tefferi will have positive thoughts about Imetelstat. The FDA must already be aware of what they are going to say, and is preparing some follow-up comments shortly after. These next 2 weeks could (should ??) be very good foe GERN's stock price.
The FDA is a mystery, but, one would think, their only interests are the health, welfare and safety of the patients. (Some on this board think that they are not 100% clean & honest. I hope that is not true). With talks by Scarlett (April 8) and Tefferi (April 12) we will likely find out what the hang-ups are. That should be very good for Geron and Imetelstat. Let's hope that Geron, the FDA, and Mayo are all on the same page, and will speak in unity with a well thought out game plan going forward.
Mayo has spoken through Dr. Tefferi, and his input is excellent. There are only the low-level liver considerations to think about. The FDA is silent at the moment. To be on the "same-side" you don't have to think in exactly the same way. There is no doubt that both want to help the cancer patients, so they are both on the same side. Clearly their missions are different. Mayo's data is sound and compelling, but the FDA still has to verify that officially (that is how the system works). The people that are in a hurry want their lives prolonged, with a possible cure insight; that seems to be where the FDA is open to criticism.
I think the nay-saying bashers and manipulators are almost out of ammunition. Mayo and the FDA will present a unified front with good news.
My son, may the angles take kindly to your totally shorted brain inner-connections. It is not your fault that you were denied the insight of others.
You must be a very dull human, not being able to absorb the future of technology and the "3rd Industrial Revolution". MSFT took a nap, but they are back in all of their glory, with deep pockets and Asian brains, that were lacking in the past.
MSFT has survived the "bad years" with excellent profits, but not much innovation. We will now see the "second-coming" of Bill Gates, who was taken to the cleaners by Steve Jobs (mobile devices), but now has a "new-awakening" about the direction of technology. MSFT will surprise everyone with new vigor and innovation.
Mayo is very cautious in their pronouncements. We would like to hear from them more often. A monthly update about telomeres and cancer therapies would be interesting to all, including patients and investors. Of course, Mayo is only interested in the progress of cancer patients, when testing new, innovative drugs (good and bad features).
The combination of Indian brilliance (Satya Nadella) in the "cloud" as CEO, and Bill Gates (technical and financial savvy) is bringing MSFT back to their former status as a top technical innovator, and a strong investment at these low PE's. MSFT has had the financial strength to succeed, but lacked the proper leadership under Ballmer. That has all changed for the better, plus MSFT is now a global enterprise. Practical, profitable spin-offs are coming soon.
I believe that we have been told. The drug works for many, but not all. That has been one of the questions all along, and part of the research behind genetic markers and switches, where this drug is concerned. Obviously, there is still much to learn. In other cases, patients were very sick from the get-go.
Only a Southern White Man, with a Civil War Mentality, could think like this. You have "Ted Cruz" written all over your posting.
Bloomberg, March 23---During our current gilded age, billionaires are betting on science. Larry Ellison, founder of software maker Oracle Corp. and the world’s eighth-richest man, according to the Billionaires Index, funds the Ellison Medical Foundation to study longevity. The foundation supports research on telomeres, the protective caps on the ends of chromosomes that have been linked to how rapidly we age.
Black: It is probably a good thing, from both an investor's point of view and a cancer patient's hope, that Geron's future is tied so closely to Mayo's studies and research. That means that we will get the truth, even though we may have to wait awhile (not too long, I believe) for a complete, accurate and detailed report (with no frauds or hoaxes). In addition, it will be updated periodically. Mayo cannot be compromised. That also holds for Dr. Tefferi, as a Mayo spokesman.
We don't know the total "market for Imetelstat", and related drugs. We do know of near term successes in certain blood cancers, and continuing discussions about "low-order" side effects mostly about the liver with the FDA. Telomeres and the genetic process have won a Nobel Prize, so this subject will initiate many more studies (ageing, cancer stemcells, genetic markers. chromosomes, genetic switches, combinations, etc.).
Telomeres are one of the building blocks of life, and biological science. My pure "conjecture" is that telomere-science will have a very positive impact in improved treatments for some of our most difficult diseases, and will significantly change our academic understandings. Geron also holds significant patents.
I have no way of knowing Geron's future as an independent company, but I am sure their future is tied to Mayo Clinic's research, and, most likely, associations (partners, mergers, etc.) with other very solid drug companies with similar interests. The science is solid, and, I believe, medical successes are coming. There is always the possibility that we may be very disappointed by unforeseen events, but that is why this is a speculative investment, and not a sure thing.
Mayo needs an associate, merger or a partner that has deep pockets, is already dedicated to cancer cures, and understands the near term and long term concept of a pipeline. Geron, with a product that has huge potential, has a flawed past that they cannot shake off. The market manipulators, playing in narrow channels, are making Geron dance to their tune. The FDA's approach is cloudy at best, and Geron appears to be the looser.